Trials / Completed
CompletedNCT05989711
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 212 (actual)
- Sponsor
- Altimmune, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Detailed description
A Phase 2, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in NASH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemvidutide | Administered by subcutaneous injection |
| DRUG | Placebo | Administered by subcutaneous injection |
Timeline
- Start date
- 2023-07-27
- Primary completion
- 2025-04-29
- Completion
- 2025-11-25
- First posted
- 2023-08-14
- Last updated
- 2025-12-26
Locations
40 sites across 3 countries: United States, Australia, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05989711. Inclusion in this directory is not an endorsement.